How Immune Aging Fuels Breast Cancer and Blocks Immunotherapy

Breast cancer affects approximately 2.3 million women annually, with the median diagnosis age of 62 placing most patients squarely within the window of age-related immune decline. This comprehensive 2026 review from Lei and Guo critically examines how immunosenescence—encompassing thymic involution, T cell receptor repertoire contraction, senescent immune cell accumulation, and chronic low-grade inflammation (inflammaging)—may actively drive breast cancer progression and blunt immunotherapy responses, while carefully distinguishing established mechanisms from correlative observations.

The authors provide one of the most detailed taxonomies of immune dysfunction in the breast tumor microenvironment to date. T cell senescence and exhaustion are rigorously distinguished: exhausted T cells retain partial proliferative capacity and can be reinvigorated by checkpoint blockade, while truly senescent T cells—marked by loss of CD28, elevated p16INK4a/p21, telomere shortening, and mitochondrial ROS production—are refractory to PD-1/PD-L1 inhibition. A key mechanistic finding highlighted is that type I interferon signaling from HLA-DR+ monocytes activates the IRF9–PARP axis in CD8+ T cells, depleting NAD+ and driving metabolic collapse into senescence—directly linking innate immune signaling to CD8+ T cell dysfunction in early-stage TNBC. NK cells are similarly impaired via TGF-β1-mediated downregulation of activating receptors (NKG2D, NKp30, DNAM-1) and upregulation of inhibitory NKG2A, with severity correlating with tumor aggressiveness and reversible upon tumor resection.

The senescence-associated secretory phenotype (SASP)—comprising IL-6, IL-8, TGF-β, and matrix metalloproteinases—emerges as a central nexus connecting cellular senescence to immune evasion, epithelial-mesenchymal transition, and metastatic spread. Cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs) are identified as key orchestrators, remodeling the extracellular matrix, excluding effector immune cells, and sustaining immunosuppressive cytokine gradients. Therapy-induced senescence (TIS) following chemotherapy and radiotherapy is discussed as a paradoxical driver of relapse through SASP-mediated immunomodulation, though the authors note this concept lacks prospective clinical validation in breast cancer patients.

Subtype-specific and hormonal dimensions receive detailed treatment. TNBC, while most immunogenic, shows the most pronounced senescence-related ICI resistance. HR+ tumors exhibit estrogen-driven Treg accumulation. Menopausal estrogen decline accelerates immune aging. BRCA1/2 mutation carriers display a distinct immunosenescence trajectory. Aging is associated with diminished interferon signaling, reduced tumor-infiltrating lymphocyte density, and altered checkpoint blockade efficacy, though inter-patient heterogeneity is substantial.

Emerging therapeutic strategies include senolytics (navitoclax targeting BCL-2/BCL-XL; dasatinib plus quercetin; fisetin), senomorphics to suppress SASP without inducing apoptosis, NAD+ repletion via NMN or NR to rescue metabolic T cell dysfunction, STING agonists to restore innate immune sensing, and rational combinations of senotherapy with ICIs. The authors conclude that targeting tumor immunosenescence is a promising but incompletely validated axis, with most interventions at preclinical or early clinical stages requiring rigorous prospective evaluation.